The reiterated Buy rating and maintained $9 price target by HC Wainwright & Co. analyst Raghuram Selvaraju is a positive signal for Regulus Therapeutics (NASDAQ:RGLS). This reaffirms the analyst's confidence in the company's potential, which could lead to increased investor interest and a short-term positive impact on the stock price.